Dyne Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial, DELIVER, evaluating DYNE-251 for the treatment of Duchenne muscular dystrophy mutations amenable to exon 51 skipping.
[Dyne Therapeutics, Inc.]